Coherus BioSciences (CHRS) Tops Q4 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.04 +1.96%
Revenue Growth %: +37.8%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
SICP, MNSB, CFFI, More
Revenue Growth %: +37.8%
Financial Fact:
Income tax provision/(benefit): 6.81M
Today's EPS Names:
SICP, MNSB, CFFI, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($0.60), $0.20 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $45.35 million versus the consensus estimate of $48.41 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Reiterates Neutral Rating on Nike (NKE) on Expected Pace of Earnings Recovery
- Roper Technologies (ROP) Tops Q3 EPS by 10c ; Offers Guidance
- Carpenter Technology (CRS) Tops Q1 EPS by 21c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
